Interstitial

Physicians’ Education Resource® to Present an Interactive, Case-Based Discussion: Improving Outcomes in Progressive Fibrosing-Interstitial Lung Disease Through Early and Accurate Diagnosis

Retrieved on: 
Thursday, April 25, 2019
Education, Continuing, Other Education, Health, Hospitals, Radiology, Research, Other Science, Science, Interstitial lung disease, Otorhinolaryngology, Pulmonology, Respiratory system, Interstitial, Respiratory disease, Pneumonia

Physicians Education Resource (PER), a worldwide leading resource for continuing medical education (CME), will conduct the CME-Certified satellite symposium Improving Outcomes in Progressive Fibrosing-Interstitial Lung Disease (PF-ILD) Through Early and Accurate Diagnosis, adjunct to the 2019 American Roentgen Ray Society (ARRS) Annual Meeting.

Key Points: 
  • Physicians Education Resource (PER), a worldwide leading resource for continuing medical education (CME), will conduct the CME-Certified satellite symposium Improving Outcomes in Progressive Fibrosing-Interstitial Lung Disease (PF-ILD) Through Early and Accurate Diagnosis, adjunct to the 2019 American Roentgen Ray Society (ARRS) Annual Meeting.
  • The live programwill take place Thursday, May 9, from 11:30 a.m. to 12:30 p.m. at the Hawaii Convention Center in Honolulu.
  • We look forward to presenting this program at this years ARRS Annual Meeting, said Phil Talamo, president of PER.
  • Progressive fibrosing-interstitial lung disease is a serious pulmonary disorder, and it is very important that clinicians are up to date on improving the diagnosis of the disease in effort to improve patient management and optimizing overall outcomes.

Interstitial Cystitis - Pipeline Insights, 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 24, 2019
Health, Pharmaceutical, Urinary bladder disorders, Drug pipeline, Food and Drug Administration, Interstitial, Pipeline, Medical specialties, Medicine

The "Interstitial Cystitis - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interstitial Cystitis - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interstitial Cystitis development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • clinical, pre-clinical and discovery stages for Interstitial Cystitis
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Interstitial Cystitis
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
    An Overview of Pipeline Products for Interstitial Cystitis-Pipeline Insights, 2019

The interstitial cystitis drugs market will register a CAGR of almost 3% by 2023

Retrieved on: 
Wednesday, March 27, 2019
Organ systems, Medical specialties, Urinary bladder disorders, Interstitial, Dimethyl sulfoxide, Pentosan polysulfate, Medicine

Technavio's analysts have predicted that the interstitial cystitis drugs market will register a CAGR of almost 3% by 2023.

Key Points: 
  • Technavio's analysts have predicted that the interstitial cystitis drugs market will register a CAGR of almost 3% by 2023.
  • Currently, the global interstitial cystitis drugs market has only two approved drugs, ELMIRON and RIMSO-50 (dimethyl sulfoxide).
  • For the detailed list of factors that will drive and challenge the growth of the interstitial cystitis drugs market during the 2019-2023, view our report.
  • Factors such as the increasing awareness of interstitial cystitis and the advent of gene therapy, will provide considerable growth opportunities to interstitial cystitis drugs manufactures.

Global Interstitial Cystitis Drugs Market Outlook, 2019-2023 - Advent of Gene Therapy to Drive Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 14, 2019
Health, Pharmaceutical, Medical specialties, Organ systems, Medicine, Urinary bladder disorders, Interstitial cystitis, RTT, Infectious diseases, Dimethyl sulfoxide, Pentosan polysulfate, Interstitial, Urinary tract infection

The "Global Interstitial Cystitis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Interstitial Cystitis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The interstitial cystitis drugs market will register a CAGR of almost 3% by 2023.
  • The treatment of interstitial cystitis consists of oral therapy and intravesical therapy as the first- and second-line treatment options, respectively.
  • Currently, the global interstitial cystitis drugs market has only two approved drugs, ELMIRON and RIMSO-50 (dimethyl sulfoxide).